CoChat

Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury

Open access
Tamargo, Ian A., Bader, Miaad, Li, Yazhou, Yu, Seong-Jin, Wang, Yun, Talbot, Konrad, DiMarchi, Richard D., Pick, Chaim G., Greig, Nigel H. · 2017 · Experimental Neurology
Cited by 42

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Several single incretin receptor agonists that are approved for the treatment of type 2 diabetes mellitus (T2DM) have been shown to be neuroprotective in cell and animal models of neurodegeneration. Recently, a synthetic dual incretin receptor agonist, nicknamed “twincretin,” was shown to improve upon the metabolic benefits of single receptor agonists in mouse and monkey models of T2DM. In the current study, the neuroprotective effects of twincretin are probed in cell and mouse models of mild traumatic brain injury (mTBI), a prevalent cause of neurodegeneration in toddlers, teenagers and the elderly. Twincretin is herein shown to have activity at two different receptors, dose‐dependently increase levels of intermediates in the neurotrophic CREB pathway and enhance viability of human neuroblastoma cells exposed to toxic concentrations of glutamate and hydrogen peroxide, insults mimicking the inflammatory conditions in the brain post‐mTBI. Additionally, twincretin is shown to improve upon the neurotrophic effects of single incretin receptor agonists in these same cells. Finally, a clinically translatable dose of twincretin, when administered post‐mTBI, is shown to fully restore the visual and spatial memory deficits induced by mTBI, as evaluated in a mouse model of weight drop close head injury. These results establish twincretin as a novel neuroprotective agent and suggest that it may improve upon the effects of the single incretin receptor agonists via dual agonism. Graphical abstract Figure. No caption available. HighlightsThe dual GLP‐1/GIP receptor agonist “twincretin” was evaluated for neurotrophic and neuroprotective actions in cell and in vivo models of mild TBI.Twincretin provided neurotrophic properties in immortal human SH‐SY5Y neuronal cells ‐ elevating cAMP levels and pCREB.Twincretin provided neuroprotection against oxidative stress and glutamate excitotoxicity in human SH‐SY5Y cells.Twincretin protected rat primary cultures of dopaminergic ventral mesencephalon neurons from 6‐hydroxydopamine‐induced injury.A clinically translatable dose of twincretin fully mitigated mild TBI‐induced spatial and visual memory deficits in a mouse close head injury model.Twincretin mediated mitigation of cellular and in vivo TBI‐induced impairments highlight the agent for evaluation in neurodegenerative disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2016.11.005

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 42

Metadata

Authors
Tamargo, I. A., Bader, M., Li, Y., Yu, S.-J., Wang, Y., Talbot, K., DiMarchi, R. D., Pick, C. G., & Greig, N. H.
Venue
Experimental Neurology
Publisher
Elsevier BV
Published
2017-02
Volume
288
Pages
176-186
ISSN
0014-4886 (ISSN-L)
OpenAlex
W2554906677
Cited by
42
References
14
FWCI
4.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury. https://app.cochat.ai/papers/10.1016/j.expneurol.2016.11.005
The paper
Tamargo, I. A., Bader, M., Li, Y., Yu, S.-J., Wang, Y., Talbot, K., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2017). Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury. Experimental Neurology. https://doi.org/10.1016/j.expneurol.2016.11.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.